Mirtazapine Sandoz 30

Mirtazapine, the active ingredient in Mirtazapine Sandoz 30, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as a 30 mg tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapine Sandoz 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Products are manufactured under EU GMP guidelines and undergo rigorous batch release testing.

Mirtazapine, a noradrenergic and specific serotonergic antidepressant, is used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adults. - Depressive episodes associated with major depressive disorder: alleviates core symptoms such as low energy and anhedonia. - Adjunctive treatment of anxiety symptoms in depressive disorders: may help reduce associated anxiety and improve sleep.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness. - Increased appetite leading to weight gain. - Dry mouth. - Constipation. - Dizziness. - Fatigue.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Severe allergic reactions such as anaphylaxis. - Seizures. - Emergence or worsening of suicidal thoughts. - Hepatic dysfunction.

Before prescribing mirtazapine, clinicians should consider several safety aspects.

- Assess psychiatric history: evaluate for suicidal ideation before initiating therapy. - Monitor weight: watch for significant weight gain during treatment. - Check liver function: adjust use in patients with hepatic impairment. - Caution in elderly: increased risk of sedation, falls, and orthostatic hypotension. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal effects. - Store at ambient temperature: keep below 25 °C, in the original packaging, and protect from moisture and light.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation. - Serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may increase mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine): may reduce therapeutic efficacy. - Antihistamines: additive anticholinergic effects may increase sedation.